Neuromuscular Dysfunction of the Lower Urinary Tract with Special Reference to the Influence of the Sympathetic Nervous System

1981 ◽  
Vol 15 (1) ◽  
pp. 7-19 ◽  
Author(s):  
J. Nordling ◽  
H. H. Meyhoff ◽  
T, Hald
Keyword(s):  
Nervous System ◽  
Urinary Tract ◽  
Sympathetic Nervous System ◽  
Special Reference ◽  
Lower Urinary Tract ◽  
Neuromuscular Dysfunction ◽  
Sympathetic Nervous ◽  
Lower Urinary

Sympathetic nervous system and dysfunction of the lower urinary tract

1986 ◽  
Vol 70 (S14) ◽  
pp. 69s-76s ◽  
Author(s):  
N. J. R. George ◽  
C. Reading
Keyword(s):  
Nervous System ◽  
Urinary Tract ◽  
Sympathetic Nervous System ◽  
Lower Urinary Tract ◽  
Homogeneous Group ◽  
Adrenergic Mechanisms ◽  
Detrusor Function ◽  
Sympathetic Nervous ◽  
Urethral Function ◽  
Lower Urinary

Careful clinical and investigative protocols allow the identification of a homogeneous group of patients with prostatodynia or ‘anxious bladder syndrome’ (underactive detrusor function). Psychophysiological studies and urodynamic measurements in such patients demonstrate remarkably consistent results, which, whilst lending support to the hypothesis that the sympathetic nervous system may affect bladder and urethral function, do not offer objective proof that adrenergic mechanisms are directly responsible for the observed dysfunctional state.

scholarly journals Pathophysiology of the lower urinary tract and CNS

2013 ◽  
Vol 5 (5-S2) ◽  
pp. 126
Author(s):  
Christopher Chapple
Keyword(s):  
Spinal Cord ◽  
Central Nervous System ◽  
Nervous System ◽  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Neural Control ◽  
Neural Mechanisms ◽  
The Other ◽  
Bladder Function ◽  
Lower Urinary

A number of aspects of neural control are potentially important inthe control of bladder function, including both sensory and motorand peripheral and central pathways. It is likely that a combinationof disorders of both central and peripheral neural mechanisms isimportant in the genesis of urgency and the other symptoms of theoveractive bladder (OAB). Given the number of potential pathwaysinvolved, potential pharmacologic targets for OAB exist in the CNS(central nervous system; cerebral cortex, midbrain, spinal cord)and periphery (LUT; lower urinary tract). Antimuscarinics are stillthe mainstay of OAB treatment, but there are also a number ofother potentially efficacious drugs that may also provide benefitagainst the neurologic components of OAB. This review discussesthe impact of neurological abnormalities on lower urinary tractsymptoms and the potential for treatments targeting these pathwaysto improve symptoms.

Sign in / Sign up

Export Citation Format

Share Document